Section Arrow
PRME.NASDAQ
- Prime Medicine
Quotes are at least 15-min delayed:2026/04/22 11:52 EDT
Regular Hours
Last
 3.935
+0.125 (+3.28%)
Day High 
3.97 
Prev. Close
3.81 
1-M High
3.96 
Volume 
832.40K 
Bid
3.93
Ask
3.94
Day Low
3.81 
Open
3.82 
1-M Low
3.04 
Market Cap 
687.90M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.68 
20-SMA 3.55 
50-SMA 3.67 
52-W High 6.94 
52-W Low 1.11 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.35/-0.94
Enterprise Value
796.19M
Balance Sheet
Book Value Per Share
0.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.63M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.2138+0.017+8.64%-- 
REPLReplimune Group2.165+0.305+16.40%-- 
IOVAIovance Biotherapeutics3.44-0.26-7.03%-- 
TOVXTheriva Biologics Inc0.358801+0.020101+5.93%0.09PE
OCGNOcugen1.695-0.075-4.24%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations,acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.